ONCAlert | 2017 San Antonio Breast Cancer Symposium

Challenges With PARP Inhibitors in Ovarian Cancer

Kathleen N. Moore, MD
Published Online:9:58 AM, Wed August 16, 2017

Kathleen N. Moore, MD, assistant professor in the section of gynecologic oncology and director of the Oklahoma TSET Phase I Clinical Trials Program at the University of Oklahoma Health Sciences Center, discusses challenges with PARP inhibitors in ovarian cancer.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.